据招股书，2023年-2024年，京新药业实现收入分别为40亿元、41.59亿元；年内溢利分别为6.23亿元、 7.19亿元。 2025年前10个月，公司实现收入为33.44亿元，同比减少2.74%；期内溢利为6.29亿元，同比增长 12.69%。 | | 截至12月31日止年度 | | 截至10月31日止十個月 | | | --- | --- | --- | --- | --- | | | 2023年 | 2024年 | 2024 年 | 2025年 | | | | | (未經審核) | | | | | (人民幣千元) | | | | 收入 | 3.998.835 | 4.158.551 | 3.438.388 | 3.344.144 | | 銷售成本 | (2,032,050) | (2,143,031) | (1,757,318) | (1,730,246) | | 毛利 | 1.966.785 | 2.015.520 | 1.681.070 | 1.613.898 | | 其他收入 | 118.741 | 184.443 | 143,423 | 89.798 | | 预期信貸虧損模式項下的 | | | ...

Core Viewpoint - Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, focusing on innovation-driven pharmaceutical development in central nervous system and cardiovascular diseases [3]. Financial Performance - The company projects revenues of RMB 4 billion and RMB 4.16 billion for 2023 and 2024, respectively, with net profits of RMB 623 million and RMB 719 million for the same years [4]. - For the first ten months of 2025, the company reported revenues of RMB 3.34 billion, a decrease of 2.74% year-on-year, while net profit increased by 12.69% to RMB 629 million [3][4]. Business Model - Jingxin Pharmaceutical's business model combines the commercialization of existing products with the ongoing development of its product pipeline, which includes a range of pharmaceuticals, active pharmaceutical ingredients, and medical devices [3]. Shareholding Structure - The company is controlled by a group of shareholders led by Executive Director and Chairman Lv Gang, who directly holds approximately 20.77% of the company, while Jingxin Holdings and Jinzhihua Investment hold 15.68% and 51% of Jingxin Holdings, respectively [5]. Leadership - Lv Gang, aged 63, has been with the company since 1999 and has held various leadership roles, including Executive Director and General Manager, responsible for strategic planning and overall operations [9][10]. - Hong Yunfei, aged 46, joined the company in 2005 and is currently the Executive Director and Secretary of the Board, overseeing strategic investments and chemical research [11].

Group 1 - The core viewpoint of the article is that Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - Jingxin Pharmaceutical is characterized as an innovation-driven pharmaceutical group focusing on two main disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases [1] - The company's business model combines the commercialization of already listed products with the continuous advancement of its product pipeline [1] Group 2 - The current product portfolio includes drugs (such as generic drugs, innovative drugs, traditional Chinese medicine, and biological agents), active pharmaceutical ingredients, and medical devices [1]